DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: OCREVUS (ocrelizumab)
*****************************************************
#Post#: 3213--------------------------------------------------
Fatal PML case in 78-year-old patient on Ocrevus monotherapy
DIR By: agate
Date: March 16, 2021, 5:55 pm
---------------------------------------------------------
From JAMA Neurology (March 16, 2021), "Progressive multifocal
leukoencephalopathy in a patient with progressive multiple
sclerosis treated with ocrelizumab monotherapy":
HTML http://bit.ly/3eQm9ii
#Post#: 3214--------------------------------------------------
MedPage Today) PML reported in ocrelizumab-treated MS patient
DIR By: agate
Date: March 18, 2021, 1:28 am
---------------------------------------------------------
From MedPage Today (March 17, 2021)--"PML reported in
ocrelizumab-treated MS patient":
HTML https://www.medpagetoday.com/neurology/multiplesclerosis/91647
#Post#: 3216--------------------------------------------------
(Medscape) First case of PML associated with ocrelizumab
monotherapy
DIR By: agate
Date: March 20, 2021, 12:43 am
---------------------------------------------------------
This is the third article I've found on this topic, and so far
there is no indication of how long the patient had had MS. It
might be helpful to know that.
Medscape (March 29, 2021)--"First case of PML associated with
ocrelizumab monotherapy":
HTML https://www.medscape.com/viewarticle/947765#vp_2
#Post#: 3219--------------------------------------------------
Re: Fatal PML case in 78-year-old patient on Ocrevus monotherapy
DIR By: agate
Date: March 23, 2021, 1:10 am
---------------------------------------------------------
The first article mentioned in this thread contains this
information about the patient.
--- Quote ---
> The patient had been diagnosed with MS almost 3 decades prior
after developing gradual gait dysfunction and bilateral
asymmetric leg weakness throughout several years. Despite
continued slow gait worsening over years, he had not been
treated with immunotherapy until ocrelizumab was approved by the
US Food and Drug Administration for primary progressive MS in
2017. He began taking ocrelizumab at age 76 years soon after
Food and Drug Administration approval. The patient’s JCV index
was 2.48 prior to initiation, and the theoretical risk of PML
was discussed prior to starting. He tolerated the treatments
well but continued to exhibit worsening gait dysfunction.
--- End Quote ---
[/size]
[/size]One wonders why a patient of 76 who has had PPMS for some
30 years would have been prescribed ocrelizumab.
*****************************************************
Page 1 of 1